Rapid Biosensor Systems appoints chair in move to IPO
12 August 2014
Cambridge company Rapid Biosensor Systems Ltd has appointed John
Reynolds OBE as Executive Chairman to take it to the next stage of
The company has developed a unique breathalyser technology for
the screening of active tuberculosis that can be used in any type of
location to give rapid low-cost results.
Reynolds has chaired the Church of England’s Ethical Investment
Advisory Group, is a director of a number of companies, including
Northern Powergrid Holding Company and the Central Finance Board of
the Methodist Church, and was awarded an OBE in 2012 in recognition
for his services to Save the Children.
He has extensive experience of advising and financing companies
from early stage to Fortune 500 in the UK, Europe, Asia and the US,
and has led the sale of pre-revenue companies for major financial
investors as well as FTSE100 corporates.
Dennis Camilleri CEO and Co-Founder of Rapid Biosensor said: “We
are delighted to have the opportunity to work with John who is
already creating significant traction with global investment groups.
Our company has successfully tested its product in India and
Ethiopia, and the results indicate it will make a real contribution
to healthcare improvements worldwide. The technology will also
provide the basis for other medical devices and the company is
preparing for an IPO in the near future.
About the technology
The RBS TB Breathalyser incorporates a range of technologies that
allow for full portability and almost instant results. It can be
assembled without the need for clean room conditions and may be used
by non-medical personnel, so is particularly suitable for use in
The breathalyser incorporates a single-use disposable sample
collection tube (10cm x 3.5cm) and a multi-use reader. After being
nebulised (if necessary) using a 0.9% saline solution, the patient
then coughs into the collection tube, at the bottom of which is a
glass bio-sensor coated with a patented bio-chemical coating
formulated to react with the TB bacilli. A simple push-and-twist
action automatically seals the aerosol sample in the tube and
deposits it on the bio-sensor. The tube is then inserted into the
reader and twisted to switch on the unit.
The biochemical coating contains fluorescent chemicals that are
displaced by TB antigen and so when excited by the laser return a
reduced signal if TB is present in the sample. The laser detects
this signal change and the unit returns a positive result. Reading
and analysis of the sample takes about two minutes.
Source: Rapid Biosensor systems